Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bradley Hupf

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Statistics in Medicine|April 14, 2021
Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trialsBradley Hupf, Veronica Bunn, Jianchang Lin, et al.
Journal of Biopharmaceutical Statistics|June 23, 2022
Bayesian Additive Regression Trees (BART) with covariate adjusted borrowing in subgroup analysesJane Pan, Veronica Bunn, Bradley Hupf, et al.
Statistics in Medicine|June 14, 2021
Propensity-score-based meta-analytic predictive prior for incorporating real-world and historical dataMeizi Liu, Veronica Bunn, Bradley Hupf, et al.
Journal of Biopharmaceutical Statistics|April 2, 2024
Covariate adjusted meta-analytic predictive (CA-MAP) prior for historical borrowing using patient-level dataBradley Hupf, Yunlong Yang, Ryan Gryder, et al.
Clinical Pharmacology in Drug Development|June 15, 2026
A Phase 1 Study to Assess the Relative Bioavailability of Brigatinib Administered as an Oral Solution Versus an Immediate-Release Tablet in Healthy AdultsMichael J Hanley, Ronald Gounden, Bradley Hupf, et al.
Blood Cancer Discovery|April 17, 2026
A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaJustin M Darrah, Indumathy Varadarajan, Amitkumar Mehta, et al.
Lung Cancer (Amsterdam, Netherlands)|February 9, 2025
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trialsD Ross Camidge, Shunichi Sugawara, Masashi Kondo, et al.
Future Oncology (London, England)|December 18, 2025
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trialMyung-Ju Ahn, Angelo Delmonte, Sharmistha Ghosh, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Statistics in Medicine|April 14, 2021
Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trialsBradley Hupf, Veronica Bunn, Jianchang Lin, et al.
Journal of Biopharmaceutical Statistics|June 23, 2022
Bayesian Additive Regression Trees (BART) with covariate adjusted borrowing in subgroup analysesJane Pan, Veronica Bunn, Bradley Hupf, et al.
Statistics in Medicine|June 14, 2021
Propensity-score-based meta-analytic predictive prior for incorporating real-world and historical dataMeizi Liu, Veronica Bunn, Bradley Hupf, et al.
Journal of Biopharmaceutical Statistics|April 2, 2024
Covariate adjusted meta-analytic predictive (CA-MAP) prior for historical borrowing using patient-level dataBradley Hupf, Yunlong Yang, Ryan Gryder, et al.
Clinical Pharmacology in Drug Development|June 15, 2026
A Phase 1 Study to Assess the Relative Bioavailability of Brigatinib Administered as an Oral Solution Versus an Immediate-Release Tablet in Healthy AdultsMichael J Hanley, Ronald Gounden, Bradley Hupf, et al.
Blood Cancer Discovery|April 17, 2026
A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaJustin M Darrah, Indumathy Varadarajan, Amitkumar Mehta, et al.
Lung Cancer (Amsterdam, Netherlands)|February 9, 2025
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trialsD Ross Camidge, Shunichi Sugawara, Masashi Kondo, et al.
Future Oncology (London, England)|December 18, 2025
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trialMyung-Ju Ahn, Angelo Delmonte, Sharmistha Ghosh, et al.
Pageof 1